Experimental HIV vaccine shows promise in early safety trial
NCT ID NCT06253533
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a therapeutic DNA vaccine called ICVAX in 45 people with HIV who were already stable on antiretroviral therapy (ART). The goal was to see if the vaccine is safe and whether it can boost the immune system to better control the virus. Participants received different doses of the vaccine or a placebo, and researchers monitored side effects and immune responses for up to 60 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICVAX (HIV therapeutic DNA vaccine)
What this could lead to
If successful, this could point toward a way to help the immune system control HIV without daily medication.
What could go wrong
This is a very early Phase 1 trial with only 45 people, so it is mainly checking safety. It may not show strong immune effects or lead to a functional cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Third People's Hospital
Shenzhen, Guangdong, 518112, China